Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Al-Azhar Univ. VEGFR-2 compound 13
- Development stage
- Unknown
- Lead developer
- Al-Azhar University
01
Overview
Al-Azhar Univ. VEGFR-2 compound 13: sourced facts only. name: "Using ELISA, they showed mechanistically inhibitory activities against VEGFR-2; compound 13 was the most effective inhibitor, with an IC50 of 0.045 ± 6.24 uM, surpassing sorafenib (IC50 of 0.049 ± 5.24 μM)." [PMID:39864375]; target: "Using ELISA, they showed mechanistically inhibitory activities against VEGFR-2; compound 13 was the most effective inhibitor, with an IC50 of 0.045 ± 6.24 uM, surpassing sorafenib (IC50 of 0.049 ± 5.24 μM)." [PMID:39864375]; developer: "Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo 11754 Egypt. Electronic address: [email protected]." [PMID:39864375]
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Al-Azhar Univ. VEGFR-2 compound 13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Al-Azhar Univ. VEGFR-2 compound 13.